At this time, PCSK9 inhibitors are only proving to be cost-effective for high-risk ASCVD patients; however, in a patient who is unable to maintain therapy with statins, PCSK9 inhibitors may confer significant benefits (5–7, 31–41). Here, PCSK9 is linked to atherosclerosis.